Gene: UGT2B17

7367
BMND12|UDPGT2B17
UDP glucuronosyltransferase family 2 member B17
protein-coding
4q13.2
Ensembl:ENSG00000197888 MIM:601903 Vega:OTTHUMG00000129305 UniprotKB:O75795
NG_017033.1
PubMed
0   ANCO-SNPs
ND
4   
NA (AD)  NA (ND)   (Frontal_Cortex)
NA (AD)  3.781e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
SLC26A30.482
CEACAM70.44
PIGR0.426
PHGR10.405
SPINK10.365
KRT200.356
CEACAM50.344
TRIM640.342
REG1B0.341
CELA3A0.335

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
KLHL40-0.238
NRAP-0.237
PDC-0.235
RPL3L-0.225
CATSPER3-0.222
PGPEP1L-0.214
LCE1E-0.211
OR51B4-0.208
ZNF705A-0.206
RHD-0.205

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00678LosartanSmall Molecule114798-26-4ApprovedEnzyme
ID Drug Name Action PubMed
C5768821-(2-trifluoromethoxyphenyl)-2-nitroethanone1-(2-trifluoromethoxyphenyl)-2-nitroethanone results in increased expression of UGT2B17 protein22527513
C0291412,2,5,7,8-pentamethyl-1-hydroxychroman"2,2,5,7,8-pentamethyl-1-hydroxychroman results in increased expression of UGT2B17 mRNA"21920950
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of UGT2B17 mRNA"19114083
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of UGT2B17 mRNA"24878560
C0194992-nitrofluorene2-nitrofluorene results in increased expression of UGT2B17 mRNA23052194
C5830744,4'-hexafluorisopropylidene diphenol"UGT2B17 protein results in increased glucuronidation of and results in decreased activity of 4,4'-hexafluorisopropylidene diphenol"24349450
C0995654-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-olUGT2B17 gene polymorphism results in decreased glucuronidation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol17416778
C0995654-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-olUGT2B17 protein results in increased glucuronidation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol17416778|2645212
C0995644-((methylnitrosoamino)-1-(3-pyridyl)but-1-yl)beta-omega-glucosiduronic acidUGT2B17 protein results in increased chemical synthesis of 4-((methylnitrosoamino)-1-(3-pyridyl)but-1-yl)beta-omega-glucosiduronic acid26452127
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of UGT2B17 gene27153756
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of UGT2B17 mRNA21641981
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of UGT2B17 mRNA23052194
D013196DihydrotestosteroneUGT2B17 protein results in increased metabolism of Dihydrotestosterone8798464
D015113Androstane-3,17-diol"UGT2B17 protein results in increased metabolism of Androstane-3,17-diol"8798464
D000738AndrosteroneUGT2B17 protein results in increased metabolism of Androsterone8798464
C000228aristolochic acid I[aristolochic acid I co-treated with aristolochic acid II] results in increased expression of UGT2B17 mRNA23912714
C042310aristolochic acid II[aristolochic acid I co-treated with aristolochic acid II] results in increased expression of UGT2B17 mRNA23912714
D001205Ascorbic AcidUGT2B17 protein affects the reaction [Phenobarbital results in increased abundance of Ascorbic Acid]8263600
D001280AtrazineAtrazine affects the expression of UGT2B17 mRNA22285353
D004958Estradiol[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of UGT2B17 mRNA19619570
D004958EstradiolEstradiol results in increased expression of UGT2B17 mRNA19619570
C053541bicalutamidebicalutamide results in decreased expression of UGT2B17 mRNA15638997
C006780bisphenol Abisphenol A results in decreased expression of UGT2B17 mRNA25181051
D0151248-Bromo Cyclic Adenosine Monophosphate8-Bromo Cyclic Adenosine Monophosphate results in increased expression of UGT2B17 mRNA22079614
C028031cadmium acetatecadmium acetate affects the expression of UGT2B17 mRNA16249259
D020111Chlorodiphenyl (54% Chlorine)Chlorodiphenyl (54% Chlorine) affects the expression of UGT2B17 mRNA17851650
D016572CyclosporineCyclosporine results in decreased expression of UGT2B17 mRNA27989131
C004742daidzeindaidzein results in increased expression of UGT2B17 mRNA16865672
D003907DexamethasoneDexamethasone results in increased expression of UGT2B17 mRNA21146967
D002945CisplatinCisplatin results in increased expression of UGT2B17 protein22023808
D003633Dichlorodiphenyl Dichloroethylene"[2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of UGT2B17 mRNA"24878560
D004008DiclofenacUGT2B17 protein results in increased glucuronidation of Diclofenac15843492|2226588
D004052Diethylnitrosamine[Diethylnitrosamine co-treated with Piperonyl Butoxide] results in increased expression of UGT2B17 mRNA18648771
D004052Diethylnitrosamine[indole-3-carbinol co-treated with Diethylnitrosamine] results in increased expression of UGT2B17 mRNA22129741
D002117CalcitriolCalcitriol results in decreased expression of UGT2B17 mRNA21592394
D002117Calcitriol[Testosterone co-treated with Calcitriol] results in decreased expression of UGT2B17 mRNA21592394
D0198131,2-Dimethylhydrazine"[APC protein affects the susceptibility to 1,2-Dimethylhydrazine] which results in decreased expression of UGT2B17 mRNA"27840820
D004726Endosulfan[Endosulfan co-treated with Tetrachlorodibenzodioxin] results in decreased expression of UGT2B17 mRNA26159488
D060754EquolEquol results in increased expression of UGT2B17 mRNA16865672
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in increased expression of UGT2B17 mRNA23649840
D005054EugenolUGT2B17 protein results in increased metabolism of Eugenol8798464
D005485FlutamideFlutamide results in increased expression of UGT2B17 mRNA24136188
D005557FormaldehydeFormaldehyde results in increased expression of UGT2B17 mRNA23649840
D019833GenisteinGenistein results in increased expression of UGT2B17 mRNA16865672
D005897GlafenineGlafenine results in decreased expression of UGT2B17 mRNA24136188
D017313FenretinideFenretinide results in increased expression of UGT2B17 mRNA28973697
C001381hydroxycotinineUGT2B17 protein results in increased metabolism of hydroxycotinine23936477
D006923HymecromoneHymecromone results in increased activity of UGT2B17 protein26875642
D006923Hymecromonelicochalcone A inhibits the reaction [Hymecromone results in increased activity of UGT2B17 protein]26875642
D006923HymecromoneUGT2B17 protein results in increased metabolism of Hymecromone8798464
C016517indole-3-carbinol[indole-3-carbinol co-treated with Diethylnitrosamine] results in increased expression of UGT2B17 mRNA22129741
D007501IronIron deficiency results in decreased expression of UGT2B17 mRNA16629162
C070840licochalcone Alicochalcone A inhibits the reaction [Hymecromone results in increased activity of UGT2B17 protein]26875642
D008095Lithocholic AcidLithocholic Acid results in increased expression of UGT2B17 mRNA21311750
C506658lorcaserinUGT2B17 protein results in increased carbamoylation of and results in increased glucuronidation of lorcaserin22259019
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of UGT2B17 mRNA23649840
C051752nefazodonenefazodone results in increased expression of UGT2B17 mRNA24136188
C012655nimesulidenimesulide results in increased expression of UGT2B17 mRNA24136188
C023036perfluorooctanoic acidperfluorooctanoic acid results in decreased expression of UGT2B17 mRNA18467677
C023036perfluorooctanoic acidPPARA protein promotes the reaction [perfluorooctanoic acid results in decreased expression of UGT2B17 mRNA]18467677
C023036perfluorooctanoic acidperfluorooctanoic acid results in increased expression of UGT2B17 mRNA28511854
D010578PetroleumPetroleum results in increased expression of UGT2B17 mRNA25208076
D010634PhenobarbitalPhenobarbital results in decreased expression of UGT2B17 mRNA19084549
D010634PhenobarbitalPhenobarbital results in increased activity of UGT2B17 protein8263600
D010634PhenobarbitalPhenobarbital results in increased expression of UGT2B17 mRNA8263600
D010634PhenobarbitalUGT2B17 protein affects the reaction [Phenobarbital results in increased abundance of Ascorbic Acid]8263600
D010882Piperonyl Butoxide[Diethylnitrosamine co-treated with Piperonyl Butoxide] results in increased expression of UGT2B17 mRNA18648771
D010882Piperonyl ButoxidePiperonyl Butoxide results in increased expression of UGT2B17 mRNA18544911|2248451
D010882Piperonyl ButoxideTriterpenes promotes the reaction [Piperonyl Butoxide results in increased expression of UGT2B17 mRNA]18544911
C006253pirinixic acidpirinixic acid results in decreased expression of UGT2B17 mRNA18467677
C006253pirinixic acidPPARA protein promotes the reaction [pirinixic acid results in decreased expression of UGT2B17 mRNA]18467677
C006253pirinixic acidpirinixic acid results in decreased expression of UGT2B17 mRNA22484513
C071461pregnenolone 16-acetonitrilepregnenolone 16-acetonitrile results in increased expression of UGT2B17 mRNA21311750
C045950propiconazolepropiconazole results in increased expression of UGT2B17 mRNA17178689
D011763Pyrrolizidine AlkaloidsPyrrolizidine Alkaloids results in decreased expression of UGT2B17 mRNA26100227
C446685systhanesysthane results in increased expression of UGT2B17 mRNA17178689
D013739Testosterone[Testosterone co-treated with Calcitriol] results in decreased expression of UGT2B17 mRNA21592394
D013739TestosteroneTestosterone results in decreased expression of UGT2B17 mRNA21592394
D013739TestosteroneTestosterone results in increased expression of UGT2B17 mRNA21880219
D013739TestosteroneUGT2B17 protein results in increased metabolism of Testosterone8798464
D013749Tetrachlorodibenzodioxin[Endosulfan co-treated with Tetrachlorodibenzodioxin] results in decreased expression of UGT2B17 mRNA26159488
D013749Tetrachlorodibenzodioxin[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of UGT2B17 mRNA19619570
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of UGT2B17 mRNA19619570
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of UGT2B17 mRNA21724226
D014212TretinoinTretinoin results in decreased expression of UGT2B17 mRNA23724009
C032910triadimefontriadimefon results in increased expression of UGT2B17 mRNA17178689
D014315TriterpenesTriterpenes promotes the reaction [Piperonyl Butoxide results in increased expression of UGT2B17 mRNA]18544911
C080163trovafloxacintrovafloxacin results in decreased expression of UGT2B17 mRNA24136188
C406224valdecoxibvaldecoxib results in increased expression of UGT2B17 mRNA24136188
D014635Valproic AcidValproic Acid results in decreased expression of UGT2B17 mRNA29154799
D014635Valproic AcidValproic Acid results in decreased methylation of UGT2B17 gene29154799
C025643vinclozolinvinclozolin results in increased expression of UGT2B17 mRNA22285353
C111237vorinostatUGT2B17 protein results in increased glucuronidation of vorinostat25393417
C111237vorinostat[Warfarin binds to and results in decreased activity of UGT2B17 protein] which results in decreased glucuronidation of vorinostat25393417
C111237vorinostatWarfarin inhibits the reaction [UGT2B17 protein results in increased glucuronidation of vorinostat]25393417
D014859WarfarinWarfarin binds to and results in decreased activity of UGT2B17 protein25393417
D014859Warfarin[Warfarin binds to and results in decreased activity of UGT2B17 protein] which results in decreased glucuronidation of vorinostat25393417
D014859WarfarinWarfarin inhibits the reaction [UGT2B17 protein results in increased glucuronidation of vorinostat]25393417
D014874Water Pollutants, Chemical"Water Pollutants, Chemical results in increased expression of UGT2B17 mRNA"25208076

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0001972retinoic acid bindingNOTIDA20308471  
GO:0008194UDP-glycosyltransferase activity-IBA21873635  
GO:0015020glucuronosyltransferase activity-IDA22579593  
GO ID GO Term Qualifier Evidence PubMed
GO:0008202steroid metabolic process-TAS8798464  
GO:0052695cellular glucuronidation-IDA22579593  
GO ID GO Term Qualifier Evidence PubMed
GO:0005789endoplasmic reticulum membrane-IEA-  
GO:0016020membrane-TAS8798464  
GO:0016021integral component of membrane-IEA-  
GO:0031090organelle membrane-IEA-  
GO:0043231intracellular membrane-bounded organelle-IBA21873635  
KEGG ID KEGG Term
hsa00040Pentose and glucuronate interconversions
hsa00053Ascorbate and aldarate metabolism
hsa00140Steroid hormone biosynthesis
hsa00500Starch and sucrose metabolism
hsa00514Other types of O-glycan biosynthesis
hsa00830Retinol metabolism
hsa00860Porphyrin and chlorophyll metabolism
hsa00980Metabolism of xenobiotics by cytochrome P450
hsa00982Drug metabolism - cytochrome P450
hsa00983Drug metabolism - other enzymes
hsa01100Metabolic pathways
Reactome ID Reactome Term Evidence
R-HSA-1430728MetabolismTAS
R-HSA-156580Phase II - Conjugation of compoundsTAS
R-HSA-156588GlucuronidationTAS
R-HSA-211859Biological oxidationsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
23197595Steroidogenic enzyme expression in the human fetal liver and potential role in the endocrinology of pregnancy. (2013 Mar)O'Shaughnessy PJMol Hum Reprod
23575887The effect of copy number variation in the phase II detoxification genes UGT2B17 and UGT2B28 on colorectal cancer risk. (2013 Jul 1)Angstadt AYCancer
23936477Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake. (2013)Zhu AZPLoS One
25886176Homozygous deletions of UGT2B17 modifies effects of smoking on TP53-mutations and relapse of head and neck carcinoma. (2015 Mar 31)Mafune ABMC Cancer